4D Molecular Therapeutics, Inc. (FDMT) community

FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/302% above fair value

$12.23+0.12 (+0.95%)

Close on Nov 13, 2026Market cap $882.76MP/E –Yield –

Community

Notes and questions about 4D Molecular Therapeutics from other investors

No posts about FDMT yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in 4D Molecular Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FDMT.

Compare: FDMT vs BEAM · FDMT vs RGNX · FDMT vs SGMOQ · FDMT vs MAZE · FDMT vs KYMR

Revenue growth79952.5% · median 72.9%

Operating margin-226.0% · median -299.9%

Net margin-208.6% · median -227.2%

Company	Revenue	Growth
RGNX	$174.48M	+12.0%
BEAM	$156.04M	+158.9%
KYMR	$102.24M	+133.8%
FDMT	$96.06M	+79952.5%
SGMOQ	$34.56M	-45.8%
MAZE	–	–

Company

Next earnings (est.): Mar 17, 2027, after close
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 196
Held by institutions: 80.5%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1650648

Advertisement
300 × 250

See a number that looks wrong?